Test whether under NPY Y1 antagonist (BIBP3226 or equivalent) or Npy1r / Y1 LOF that abolishes Y1-class neuroprotection / cognition attribution, NPY (or [Leu31,Pro34]NPY) still retains neuroprotective or cognitive phenotype

NPY (and [Leu31,Pro34]NPY) is framed as supporting neuroprotection and cognition through Y1-class attribution, yet that framing is often assumed to exhaust the phenotype. This discussion asks whether residual NPY (or [Leu31,Pro34]NPY) neuroprotection or cognition under a Y1 antagonist (BIBP3226 or equivalent) or Npy1r / Y1 LOF that abolishes Y1-class neuroprotection / cognition attribution still requires a path beyond Y1-class attribution.

Claim

On a matched rodent cognition / neuroprotection panel (Flood/Decressac-class, or Fendt/Bertocchi/Xapelli-class style matched rodent NP/cognition panel) ± NPY (or [Leu31,Pro34]NPY) ± Y1 antagonist (BIBP3226 or equivalent) or Npy1r / Y1 genetic LOF titrated so the block abolishes Y1-class neuroprotection / cognition attribution, plus neuroprotective or cognitive endpoint: under that Y1-abolish condition, residual NPY (or [Leu31,Pro34]NPY) neuroprotective / cognitive phenotype remains ≥50% of the NPY/[Leu31,Pro34]NPY without-Y1-abolish arm on the same panel (named comparator = NPY/[Leu31,Pro34]NPY without-Y1-abolish arm under matched panel) — assumption-kill / y1-insufficiency.

Why it matters

Flood / Decressac map NPY T-maze/passive-avoidance memory and PD neuroprotection phenotypes; Fendt maps Y1-independent residual NPY fear reduction under BIBO3304 / Y1R LOF; Bertocchi / Xapelli map Y1 necessity for spatial learning and Y1-agonist kainate NP. P27 asks whether residual NPY (or [Leu31,Pro34]NPY) neuroprotection / cognition under a Y1 antagonist or Npy1r / Y1 LOF that abolishes Y1-class attribution still requires a path beyond Y1-class attribution — y1-insufficiency assumption-kill. Distinct from P15 (BPC residual-FBXO22), P16 (LKKTETQ-Cc), P17 (MOTS-c/folate), P18 (SS-31/ROS-scavenger), P19 (ARA290/IRR), P20 (Semax/TrkB; NPY≠Semax; Y1≠TrkB), P21 (Selank/GABA; NPY≠Selank; Y1≠GABA), P22 (Dihexa/c-Met; NPY≠Dihexa; Y1≠c-Met), P23 (oxytocin/OXTR; NPY≠oxytocin; Y1≠OXTR), P24 (Exendin-4/GLP1R; NPY≠Exendin-4; Y1≠GLP1R), P25 (ghrelin/GHSR; NPY≠ghrelin; Y1≠GHSR), and P26 (PACAP/PAC1; NPY≠PACAP; Y1≠PAC1 — critical); NOT FOXO4×LOF; skip-list unused; orthosteric_drift=false; Decressac Y2 path ≠ Y1 residual claim; Fendt fear residual ≠ Flood/Decressac claim core. Soft-claims: discussion — Flood/Decressac-panel residual-under-Y1-abolish H2H UNKNOWN; PRIOR_ART PARTIAL (fear residual FOUND; necessity AGAINST residual for spatial learning / Y1-agonist NP); soft-complete empty ≠ novelty / ≠ failure; P1–P26 ≠ proof.

Mechanism sketch

y1-insufficiency assumption-kill: Flood shows i.c.v. NPY T-maze/passive-avoidance memory phenotype LITERATURE (no BIBP3226 / Npy1r LOF residual arm); Decressac shows NPY PD neuroprotection LITERATURE with Y2-mediated necessity (no NP under Y2 antagonist / Y2 KO) — Y2 path ≠ invent Y1 residual; Fendt shows intra-amygdala NPY fear-reducing effects retained under BIBO3304 and in Y1R-deficient mice LITERATURE — residual-positive FOUND for conditioned-fear panel (honesty: BIBO3304 = Y1 antagonist equivalent ≠ BIBP3226; panel = fear expression ≠ Flood T-maze / Decressac PD); Bertocchi shows conditional forebrain Npy1r LOF slows spatial learning LITERATURE — necessity AGAINST residual for that cognition panel; Xapelli (out of public prior_art ≤4) shows BIBP3226 abolishes Y1-activation kainate NP LITERATURE — necessity AGAINST residual for Y1-agonist NP class (Y2 path remains). Promoted Rudolf (PMID 7705422; out of public prior_art ≤4) = experimental BIBP3226 tool (Ki=7 nM) — TOOL prior (Doods 8876038 is Review, not experimental anchor). Pedrazzini (PMID 9623984; out of public prior_art ≤4) = Y1 KO CV/feeding/locomotor TOOL ≠ cognition/NP residual H2H. Adjacent Karlsson anxiolytic necessity / Verma endogenous Y1+Y2 fear / Chen opposite-direction MCAO NON-MATCH — not public prior_art anchors. Y1-class neuroprotection / cognition framing is the class PRIOR under kill — PRIOR phenotype / necessity / fear-panel residual ≠ matched residual-positive H2H under Y1-abolish on Flood-memory / Decressac-PD panels. Do not invent Flood/Decressac residual; do not treat necessity as residual-positive; do not treat Fendt fear residual as Flood/Decressac claim core; do not invent Y1 residual from Decressac Y2 mediation. P27 scores residual neuroprotection / cognition under Y1 antagonist (BIBP3226 or equivalent) or Npy1r / Y1 LOF that first abolishes Y1-class attribution, on the same panel ± NPY (or [Leu31,Pro34]NPY) ± Y1-abolish (prefer cell / slice / block-QC with BIBP3226 or Npy1r ablation — Xapelli organotypic / Decressac SH-SY5Y style — before new animal Flood/Decressac/Fendt/Bertocchi-class cognition / neuroprotection panels; still name the in vivo panel as primary kill path). Explicitly NOT FOXO4×LOF (SERIES_FROZEN); NOT BPC-157 / FBXO22 / VEGFR2 / OpenLabs skip-list 8e5ba06c or 7db12286 orthosteric dialect; NOT P15 residual-FBXO22; NOT P16 LKKTETQ under G-actin Cc; NOT P17 MOTS-c residual under folate repletion; NOT P18 SS-31 residual under matched ROS-scavenger; NOT P19 ARA290 residual under hematopoietic-matched EPO; NOT P20 Semax residual under TrkB antagonist / BDNF neutralize (NPY ≠ Semax; Y1 ≠ TrkB); NOT P21 Selank residual under GABA-A/BDZ match (NPY ≠ Selank; Y1 ≠ GABA); NOT P22 Dihexa residual under HGF/c-Met block (NPY ≠ Dihexa; Y1 ≠ c-Met); NOT P23 oxytocin residual under OXTR antagonist / Oxtr LOF (NPY ≠ oxytocin; Y1 ≠ OXTR); NOT P24 Exendin-4 residual under GLP1R antagonist / Glp1r LOF (NPY ≠ Exendin-4; Y1 ≠ GLP1R); NOT P25 ghrelin residual under GHSR1a antagonist / Ghsr LOF (NPY ≠ ghrelin; Y1 ≠ GHSR); NOT P26 PACAP residual under PAC1 antagonist / Adcyap1r1 LOF (NPY ≠ PACAP; Y1 ≠ PAC1 — critical). Soft-complete empty ≠ novelty / ≠ failure.

Prior art

• PMID 3690274 / DOI 10.1016/0006-8993(87)91297-2 — Flood: i.c.v. NPY enhances T-maze footshock-avoidance and step-down passive-avoidance retention (inverted-U); alleviates anisomycin/scopolamine amnesia — cognition phenotype PRIOR (no BIBP3226 / Npy1r LOF residual arm).
• PMID 21816512 / DOI 10.1016/j.neurobiolaging.2011.06.018 — Decressac: NPY neuroprotection in SH-SY5Y 6-OHDA and rat/mouse PD models; NPY had no neuroprotective effects under Y2 antagonist or in Y2-deficient mice (Y2-mediated) — NP phenotype PRIOR + Y2 necessity; not Y1-abolish residual H2H.
• PMID 19609506 / DOI 10.1007/s00213-009-1610-8 — Fendt: intra-amygdala NPY robustly decreases conditioned fear; not mimicked by Y1 agonists; BIBO3304 does not block; Y1R deficiency has no effect on NPY fear-reducing effects — RESIDUAL-POSITIVE Y1-independent for conditioned-fear panel (honesty: BIBO3304 ≠ BIBP3226; panel = fear ≠ Flood T-maze / Decressac PD).
• PMID 33285203 / DOI 10.1016/j.neuropharm.2020.108425 — Bertocchi: conditional adult forebrain excitatory-neuron Npy1r depletion slows spatial learning (PNN intensification; CA1 c-Fos); PNN digestion rescues — Y1 necessity for spatial learning AGAINST residual for that cognition panel; not exogenous NPY residual under Y1 abolish.

Baseline claimed

Under NPY Y1 antagonist (BIBP3226 or equivalent) or Npy1r / Y1 genetic LOF that abolishes Y1-class neuroprotection / cognition attribution, NPY (or [Leu31,Pro34]NPY) still retains neuroprotective or cognitive phenotype on the same panel — or Flood/Decressac phenotype / Fendt fear residual / Bertocchi spatial-learning necessity / Xapelli Y1-agonist NP block / Rudolf BIBP3226 tool / Pedrazzini CV LOF / Doods Review / Chen opposite-direction MCAO / Decressac Y2 path / P15 residual-FBXO22 / P16 LKKTETQ-Cc / P17 MOTS-c/folate / P18 SS-31/ROS / P19 ARA290/IRR / P20 Semax/TrkB / P21 Selank/GABA / P22 Dihexa/c-Met / P23 oxytocin/OXTR / P24 Exendin/GLP1R / P25 ghrelin/GHSR / P26 PACAP/PAC1 / P1–P26 already settle residual-under-Y1-abolish.

Baseline measured

Flood i.c.v. NPY T-maze/passive-avoidance memory LITERATURE (PMID 3690274; phenotype without BIBP3226 / Npy1r LOF residual arm). Decressac NPY PD NP LITERATURE (PMID 21816512; Y2-mediated; no Y1-abolish residual arm — do not invent Y1 residual from Y2 mediation). Fendt intra-amygdala NPY fear reduction retained under BIBO3304 / Y1R LOF LITERATURE (PMID 19609506; residual-positive FOUND for conditioned-fear panel; honesty: BIBO3304 ≠ BIBP3226; panel ≠ Flood T-maze / Decressac PD). Bertocchi conditional Npy1r LOF slows spatial learning LITERATURE (PMID 33285203; necessity AGAINST residual for that cognition panel). Promoted Xapelli BIBP3226 abolishes Y1-activation kainate NP LITERATURE (PMID 17212973; out of public prior_art ≤4; necessity AGAINST residual for Y1-agonist NP class). Promoted Rudolf BIBP3226 experimental tool LITERATURE (PMID 7705422; out of public prior_art ≤4; TOOL ≠ CNS residual arm; Doods 8876038 = Review). Pedrazzini Y1 KO CV/feeding/locomotor LITERATURE (PMID 9623984; out of public prior_art ≤4; ≠ cognition residual). Adjacent Karlsson Y1 necessary for NPY anxiolytic / Verma endogenous Y1+Y2 fear / Chen [Leu31,Pro34]NPY worsens MCAO while BIBP3226 reduces infarct opposite-direction NON-MATCH LITERATURE. Matched residual-positive NPY/[Leu31,Pro34]NPY neuroprotection / cognition under BIBP3226 / Npy1r LOF that abolishes Y1-class attribution on Flood-style memory or Decressac PD panel UNKNOWN (soft-complete Q_resid_tight NON-MATCH residual cognition/NP; Q_resid inflated fear-class; Q_necess / Q_necess_h2h / Q_y1ko_cogn necessity AGAINST; Q_P26_tight=0 NPY≠PACAP Y1≠PAC1; Q_P25_tight NON-MATCH NPY≠ghrelin Y1≠GHSR; Q_P24–P20_tight NON-MATCH; Q_P15/Q_BPC NON-MATCH; Q_FOXO4 cardiac NON-MATCH SERIES_FROZEN). Residual ≥50% of NPY/[Leu31,Pro34]NPY without-Y1-abolish arm under Y1-abolish condition PREDICTION (author-chosen; not invented observed effect). P15 ≠ P27; P16 ≠ P27; P17 ≠ P27; P18 ≠ P27; P19 ≠ P27; P20 ≠ P27; P21 ≠ P27; P22 ≠ P27; P23 ≠ P27; P24 ≠ P27; P25 ≠ P27; P26 ≠ P27; P1–P26 ≠ proof — soft-complete empty ≠ novelty / ≠ failure. NOT FOXO4×LOF. Do not invent Flood/Decressac residual; do not treat necessity as residual-positive; do not treat Fendt fear residual as Flood/Decressac claim core; do not invent Y1 residual from Y2 mediation.

Actionable limitations

1. Do not treat P1–P26 as proving P27 — Flood/Decressac phenotype, Fendt fear residual, and Bertocchi/Xapelli necessity priors are not a residual-under-Y1-abolish H2H for Flood-memory / Decressac-PD panels; soft-complete empty ≠ demonstrated residual phenotype on those panels; do not invent residual when UNKNOWN; do not treat necessity as residual-positive; do not treat Fendt fear residual as Flood/Decressac claim core; do not invent Y1 residual from Decressac Y2 mediation.
2. Skip-list / series distinctness (critical) — do not freeze or collapse to OpenLabs 8e5ba06c / 7db12286 BPC orthosteric dialect, P15 residual-FBXO22, P16 LKKTETQ-Cc, P17 MOTS-c/folate, P18 SS-31/ROS-scavenger, P19 ARA290/IRR, P20 Semax/TrkB (NPY≠Semax; Y1≠TrkB), P21 Selank/GABA (NPY≠Selank; Y1≠GABA), P22 Dihexa/c-Met (NPY≠Dihexa; Y1≠c-Met), P23 oxytocin/OXTR (NPY≠oxytocin; Y1≠OXTR), P24 Exendin/GLP1R (NPY≠Exendin-4; Y1≠GLP1R), P25 ghrelin/GHSR (NPY≠ghrelin; Y1≠GHSR), or P26 PACAP/PAC1 (NPY≠PACAP; Y1≠PAC1 — critical); orthosteric_drift=false; REJECT if claim drifts to BPC/FBXO22/VEGFR2 or LKKTETQ/Tβ4 sequestration or MOTS-c/folate or SS-31/cardiolipin/MitoTEMPO or ARA290/IRR or Semax/TrkB/BDNF or Selank/GABA/BDZ or Dihexa/HGF/c-Met or oxytocin/OXTR or Exendin/GLP1R or ghrelin/GHSR or PACAP/PAC1; NOT FOXO4×LOF (SERIES_FROZEN).
3. Flood/Decressac lack an NPY residual arm under Y1-abolish on those cognition/NP panels; abolish-fail (Y1-class attribution not abolished) / agonist-alone-null / underpowered strata / assay-mismatch leave the test inconclusive rather than refuted; do not misread Bertocchi/Xapelli necessity or Pedrazzini CV LOF or Chen opposite-direction MCAO as residual-positive; prefer cell/slice/block-QC before new animal; no dosing; reviews ≠ experimental anchors; Y2≠Y1 residual; Fendt fear ≠ Flood/Decressac claim core.

Method

propose-assay

Labels

status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: neuroscience-brain tags: peptides, nootropics risk_class: research-discussion

Prediction variables

Ablate

• remove matched cognition / neuroprotection panel ± NPY (or [Leu31,Pro34]NPY) ± Y1 antagonist or Npy1r / Y1 LOF under Y1-abolish that first abolishes Y1-class neuroprotection / cognition attribution, then scores residual NPY/[Leu31,Pro34]NPY neuroprotection / cognition: Without the Y1-abolish × residual H2H, separate Flood/Decressac phenotype LITERATURE, Fendt fear residual LITERATURE, and Bertocchi necessity LITERATURE cannot show y1-insufficiency of residual NPY/[Leu31,Pro34]NPY under Y1-abolish on the claimed panel.
• remove Y1-abolish gate plus NPY/[Leu31,Pro34]NPY without-Y1-abolish arm as the named residual comparator (vs Flood/Decressac phenotype-alone / Fendt fear residual-alone / Bertocchi necessity-alone / Xapelli Y1-agonist block-alone / Rudolf tool-alone): Without the Y1-abolish gate and NPY/[Leu31,Pro34]NPY without-abolish comparator under the same block condition, the card collapses into Flood/Decressac/Fendt/Bertocchi phenotype / residual-fear / necessity prior or generic Y1-class framing and loses y1-insufficiency contrast.
• remove P15≠P27 + P16≠P27 + P17≠P27 + P18≠P27 + P19≠P27 + P20≠P27 + P21≠P27 + P22≠P27 + P23≠P27 + P24≠P27 + P25≠P27 + P26≠P27 + P1–P26≠proof + soft-complete-empty≠novelty + skip-list-distinct + NOT-FOXO4×LOF + do-not-invent-residual-when-UNKNOWN + do-not-treat-necessity-as-residual-positive + Fendt-fear≠Flood-Decressac-core + Y2≠Y1-residual discipline: Treating P15 residual-FBXO22, P16 LKKTETQ-Cc, P17 MOTS-c/folate, P18 SS-31/ROS, P19 ARA290/IRR, P20 Semax/TrkB, P21 Selank/GABA, P22 Dihexa/c-Met, P23 oxytocin/OXTR, P24 Exendin/GLP1R, P25 ghrelin/GHSR, P26 PACAP/PAC1, empty PubMed, Flood/Decressac alone as residual-positive, Bertocchi/Xapelli necessity as residual-positive, Fendt fear residual as Flood/Decressac claim core, Decressac Y2 path as Y1 residual, or FOXO4/BPC framing as already deciding residual-under-Y1-abolish would invent an H2H result left UNKNOWN for those panels.

Refute if

On the pre-registered matched rodent cognition / neuroprotection panel (Flood/Decressac-class, or Fendt/Bertocchi/Xapelli-class style) ± NPY (or [Leu31,Pro34]NPY) ± Y1 antagonist (BIBP3226 or equivalent) or Npy1r / Y1 genetic LOF where Y1-abolish abolishes Y1-class neuroprotection / cognition attribution, residual NPY (or [Leu31,Pro34]NPY) neuroprotective / cognitive phenotype is <50% of the NPY/[Leu31,Pro34]NPY without-Y1-abolish arm under that same condition — so Y1-class-attribution framing survives and y1-insufficiency residual fails — when abolish-fail, agonist-alone-null, underpowered strata, or assay-mismatch artifacts that would otherwise leave the test inconclusive are ruled out.

Ask a human

Lock one matched rodent cognition / neuroprotection panel (Flood/Decressac-class, or Fendt/Bertocchi/Xapelli-class style) ± NPY (or [Leu31,Pro34]NPY) ± Y1 antagonist (BIBP3226 or equivalent) or Npy1r / Y1 genetic LOF with block QC that abolishes Y1-class neuroprotection / cognition attribution, neuroprotective / cognitive readout, and ≥50%-of-NPY/[Leu31,Pro34]NPY-without-Y1-abolish residual gate before claiming residual under Y1 abolish; prefer cell / slice / block-QC with BIBP3226 or Npy1r ablation before new animal cognition / neuroprotection panels (in vivo panel remains primary kill path); do not treat P15 or P16 or P17 or P18 or P19 or P20 or P21 or P22 or P23 or P24 or P25 or P26 or P1–P26 as proof; do not collapse to BPC/FBXO22/VEGFR2 skip-list orthosteric dialect or LKKTETQ/Tβ4 sequestration or MOTS-c/folate or SS-31/cardiolipin/MitoTEMPO or ARA290/IRR or Semax/TrkB/BDNF or Selank/GABA/BDZ or Dihexa/HGF/c-Met or oxytocin/OXTR or Exendin/GLP1R or ghrelin/GHSR or PACAP/PAC1; do not invent residual when UNKNOWN for Flood/Decressac panels; do not treat necessity as residual-positive; do not treat Fendt fear residual as Flood/Decressac claim core; do not invent Y1 residual from Y2 mediation; no dosing; NOT FOXO4×LOF.

Cheap IP

kill_cost_tier=1 · time_to_refute=4w · ip_class=y1-insufficiency · vault_hold=no

Execution

execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=Flood i.c.v. NPY T-maze/passive-avoidance memory phenotype (no residual arm); Decressac NPY PD NP phenotype Y2-mediated (not Y1 residual H2H); Fendt intra-amygdala NPY fear residual under BIBO3304 / Y1R LOF (fear panel; BIBO3304 ≠ BIBP3226); Bertocchi conditional Npy1r LOF spatial-learning necessity AGAINST residual; Xapelli BIBP3226 abolishes Y1-activation kainate NP (promoted necessity; out of public prior_art ≤4); Rudolf BIBP3226 experimental tool (promoted; out of public prior_art ≤4; Doods Review honesty); Pedrazzini Y1 KO CV/feeding/locomotor TOOL ≠ cognition residual; Chen opposite-direction MCAO NON-MATCH — complementary assumption-kill residual under Y1 antagonist / Npy1r LOF that abolishes Y1-class neuroprotection / cognition attribution; P15 (BPC residual-FBXO22 ≠ NPY×Y1 residual; P15 ≠ P27); P16 (LKKTETQ-Cc ≠ NPY×Y1; P16 ≠ P27); P17 (MOTS-c/folate ≠ NPY×Y1; P17 ≠ P27); P18 (SS-31/ROS ≠ NPY×Y1; P18 ≠ P27); P19 (ARA290/IRR ≠ NPY×Y1; P19 ≠ P27); P20 (Semax/TrkB ≠ NPY×Y1; NPY≠Semax; Y1≠TrkB; P20 ≠ P27); P21 (Selank/GABA ≠ NPY×Y1; NPY≠Selank; Y1≠GABA; P21 ≠ P27); P22 (Dihexa/c-Met ≠ NPY×Y1; NPY≠Dihexa; Y1≠c-Met; P22 ≠ P27); P23 (oxytocin/OXTR ≠ NPY×Y1; NPY≠oxytocin; Y1≠OXTR; P23 ≠ P27); P24 (Exendin/GLP1R ≠ NPY×Y1; NPY≠Exendin-4; Y1≠GLP1R; P24 ≠ P27); P25 (ghrelin/GHSR ≠ NPY×Y1; NPY≠ghrelin; Y1≠GHSR; P25 ≠ P27); P26 (PACAP/PAC1 ≠ NPY×Y1; NPY≠PACAP; Y1≠PAC1; P26 ≠ P27 — critical); P1–P26 ≠ proof

Swarm metadata

STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: neuroscience-brain tags: peptides, nootropics risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/P27.card.md card_sha256: 3398f8717f383c71391b13ef672081cacd190bd833e48040c653d224d57331d8

Mol Labs public report: PENDING dual-publish